A randomized phase II study of paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer
| Autor: | T. M. Numnum, J. D. Hainsworth, G. G. Rao |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Oncology
Sorafenib Cancer Research medicine.medical_specialty Taxane endocrine system diseases business.industry Phases of clinical research Combination chemotherapy medicine.disease female genital diseases and pregnancy complications Carboplatin chemistry.chemical_compound Regimen chemistry Paclitaxel Internal medicine medicine Ovarian cancer business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 28:TPS257-TPS257 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2010.28.15_suppl.tps257 |
| Popis: | TPS257 Background: The majority of patients diagnosed with ovarian cancer have advanced disease at the time of diagnosis, and are incurable with surgical therapy. Systemic chemotherapy, following initial cytoreductive surgery, has markedly improved the treatment of patients with advanced ovarian cancer. Standard first-line combination chemotherapy includes a taxane and a platinum agent. Further improvement in the first-line treatment of ovarian cancer will likely depend on the successful incorporation of novel, targeted agents into therapy. Several angiogenesis inhibitors have shown activity against refractory ovarian cancer. Sorafenib efficiently blocks the VEGF receptor and demonstrates antitumor activity in murine xenografts using a human ovarian cancer line (SKOV3). This randomized phase II study compares the efficacy and toxicity of a standard paclitaxel/carboplatin regimen, either alone or with the addition of sorafenib, in the first-line treatment of patients with stage III/IV ovarian cancer follow... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|